Citation Impact
Citing Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
2000 Standout
An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
2015
Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002
2007
Phase II Study of Ecteinascidin-743 in Advanced Pretreated Soft Tissue Sarcoma Patients
2004
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial
2015
The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions
2007 Standout
Tumor imaging by means of proteolytic activation of cell-penetrating peptides
2004 StandoutNobel
Tumour-cell invasion and migration: diversity and escape mechanisms
2003 Standout
Soft Tissue Leiomyosarcomas and Malignant Gastrointestinal Stromal Tumors: Differences in Clinical Outcome and Expression of Multidrug Resistance Proteins
2000
Inhibition of lymphangiogenesis‐related properties of murine lymphatic endothelial cells and lymph node metastasis of lung cancer by the matrix metalloproteinase inhibitor MMI270
2004
Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma
2009
Inflammation and cancer
2002 StandoutNature
Stem cells, cancer, and cancer stem cells
2001 StandoutNature
Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study
2008
Identification of a Selectivity Determinant for Inhibition of Tumor Necrosis Factor-α Converting Enzyme by Comparative Modeling
2003
Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
2009 Standout
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
1993
Results of Two Consecutive Trials of Dose-Intensive Chemotherapy With Doxorubicin and Ifosfamide in Patients With Sarcomas
1998
A phase II study of a novel gemcitabine plus cisplatin regimen administered every three weeks for advanced non-small-cell lung cancer
1998
Advances in hematopoietic stem cell culture
1998
Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor
2001 Standout
Molecular characterisation of soft tissue tumours: a gene expression study
2002 Standout
Development of Matrix Metalloproteinase Inhibitors in Cancer Therapy
2001
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II trial
2008
Socializing with the Neighbors
2004 Standout
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Role of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991-2001
2002
Adult Cardiac Stem Cells Are Multipotent and Support Myocardial Regeneration
2003 Standout
Strategies for MMP inhibition in cancer: innovations for the post-trial era
2002
Augmented anti-metastatic efficacy of a selective matrix metalloproteinase inhibitor, MMI-166, in combination with CPT-11
2002
Soft-Tissue Sarcomas in Adults
2005 Standout
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
2006 Standout
Ex vivo manipulation of hematopoietic stem and progenitor cells
2000
Phase II Trial Of Pegylated-liposomal Doxorubicin (Doxil™) In Sarcoma*
2003
The bone marrow niche for haematopoietic stem cells
2014 StandoutNature
Role of the N-terminal Catalytic Domain of Angiotensin-converting Enzyme Investigated by Targeted Inactivation in Mice
2004 StandoutNobel
Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study.
1998
Lung cancer: current therapies and new targeted treatments
2016 Standout
Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients
2002
Cancer genes and the pathways they control
2004 Standout
Recent advances with liposomes as pharmaceutical carriers
2005 Standout
Recent advances in MMP inhibitor design
2006
Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas
2002
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
2010 Standout
SLAM Family Receptors Distinguish Hematopoietic Stem and Progenitor Cells and Reveal Endothelial Niches for Stem Cells
2005 Standout
Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets
2002
A role for Wnt signalling in self-renewal of haematopoietic stem cells
2003 StandoutNature
Chemotherapy-Induced Nausea and Vomiting
2008 Standout
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
2004 Standout
Remodelling the extracellular matrix in development and disease
2014 Standout
Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone
2010
Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting
2010
Hematopoietic Stem-Cell Transplantation
2006 Standout
Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma
2001
A Simple Enantioconvergent and Chemoenzymatic Synthesis of Optically Active α‐Substituted Amides
2011 StandoutNobel
Overview of the clinical efficacy of investigational anticancer drugs
2003
Microenvironmental regulation of hematopoietic stem cells
1997
Soft Tissue Sarcoma: An Update on Systemic Treatment Options for Patients with Advanced Disease
2014
The signaling mechanism of ROS in tumor progression
2006
Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma
2008
Associations Between End-of-Life Discussions, Patient Mental Health, Medical Care Near Death, and Caregiver Bereavement Adjustment
2008 Standout
Randomized Clinical Trials in Soft Tissue Sarcoma
2002
JAK2, complemented by a second signal from c-kit or flt-3, triggers extensive self-renewal of primary multipotential hemopoietic cells
2002
Adjuvant Epirubicin With or Without Ifosfamide for Adult Soft-Tissue Sarcoma
2002
Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas
2009
The Canonical Notch Signaling Pathway: Unfolding the Activation Mechanism
2009 Standout
Significant clinical benefit of first‐line palliative chemotherapy in advanced soft‐tissue sarcoma
2008
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
2009 Standout
Beyond tumorigenesis: cancer stem cells in metastasis
2006
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
2009 Standout
Biomarkers in Heart Failure
2008 Standout
Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial
2012 Standout
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
2005 StandoutNature
New functions for the matrix metalloproteinases in cancer progression
2002 Standout
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Gemcitabine
1997
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
2016 Standout
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial
2002
Tumour stem cells and drug resistance
2005 Standout
Prognostic Factors for the Outcome of Chemotherapy in Advanced Soft Tissue Sarcoma: An Analysis of 2,185 Patients Treated With Anthracycline-Containing First-Line Regimens—A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study
1999
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
2014 Standout
Randomized Phase II Evaluation of 6 g/m2 of Ifosfamide Plus Doxorubicin and Granulocyte Colony-Stimulating Factor (G-CSF) Compared With 12 g/m2 of Ifosfamide Plus Doxorubicin and G-CSF in the Treatment of Poor-Prognosis Soft Tissue Sarcoma
2004
Stroma-Contact Prevents Loss of Hematopoietic Stem Cell Quality During Ex Vivo Expansion of CD34+ Mobilized Peripheral Blood Stem Cells
1998
Efficacy of Sequential High-Dose Doxorubicin and Ifosfamide Compared With Standard-Dose Doxorubicin in Patients With Advanced Soft Tissue Sarcoma: An Open-Label Randomized Phase II Study of the Spanish Group for Research on Sarcomas
2009
Matrix Metalloproteinases
2002
Characterization of hematopoietic progenitor mobilization in protease-deficient mice
2004
Randomized Phase III Study Comparing Conventional-Dose Doxorubicin Plus Ifosfamide Versus High-Dose Doxorubicin Plus Ifosfamide Plus Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Soft Tissue Sarcomas: A Trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group
2000
Stem Cell Factor and Hematopoiesis
1997
Expansionin vitroof adult murine hematopoietic stem cells with transplantable lympho-myeloid reconstituting ability
1997
Hematopoietic stem cells with controllable tEpoR transgenes have a competitive advantage in bone marrow transplantation
2000 StandoutNobel
Gene correction in hematopoietic progenitor cells by homologous recombination
2000 StandoutNobel
Proposal for classifying the acute emetogenicity of cancer chemotherapy.
1997 Standout
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
2002 StandoutScience
Immunobiology of Dendritic Cells
2000 Standout
c-kit Ligand and Flt3 Ligand: Stem/Progenitor Cell Factors With Overlapping Yet Distinct Activities
1998
Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases
2003 Standout
Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target
2003
Mammographic density. Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence
2008
Trends in the Aggressiveness of Cancer Care Near the End of Life
2004 Standout
Phase II Trial of Gemcitabine Plus Cisplatin in Patients With Metastatic Urothelial Cancer
2000
Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma.
2002
Development of human CD4+FoxP3+ regulatory T cells in human stem cell factor–, granulocyte-macrophage colony-stimulating factor–, and interleukin-3–expressing NOD-SCID IL2Rγnull humanized mice
2011 StandoutNobel
Adult Mice With Targeted Mutation of the Interleukin-11 Receptor (IL11Ra) Display Normal Hematopoiesis
1997
Selective Matrix Metalloproteinase Inhibition With Developing Heart Failure
2003
In Vitro Maintenance of Highly Purified, Transplantable Hematopoietic Stem Cells
1997
New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies
2010
Dose translation from animal to human studies revisited
2007 Standout
Works of W.P. Steward being referenced
Combination studies with gemcitabine in the treatment of non-small-cell lung cancer
1998
New drugs in the treatment of non-small cell lung cancer
1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
1995
Phase II study of fotemustine in advanced soft tissue sarcomas
1993
Oxidative stress and cyclooxygenase activity in prostate carcinogenesis: targets for chemopreventive strategies
2004
Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.
2001
Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma.
1993
Phase I/II study of gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: preliminary results.
1996
Ex vivo expansion with stem cell factor and interleukin-11 augments both short-term recovery posttransplant and the ability to serially transplant marrow
1996
Phase II study with liposomal muramyl tripeptide phophatidylethanolamine (MTP/PE) in soft tissue sarcomas (STS)
1993